Related Experiment Videos
Multidrug therapy in paucibacillary leprosy--a five year experience
A Grugni1, N J Nadkarni, M S Kini
1Lok Seva Sangam, D-1, Everard Nagar, Bombay.
Indian Journal of Leprosy
|October 1, 1988
Summary
Multidrug therapy (MDT) for paucibacillary (PB) leprosy is effective, with 69% of patients inactive after 12 doses. However, 27% remained active, highlighting the need for at least 12 MDT doses for all PB patients.
Area of Science:
- Medical research
- Infectious diseases
- Dermatology
Background:
- Leprosy, specifically paucibacillary (PB) leprosy, remains a significant public health concern.
- Multidrug therapy (MDT) is the standard treatment for leprosy.
- Determining optimal treatment duration for PB leprosy is crucial for effective disease control.
Purpose of the Study:
- To evaluate the efficacy of multidrug therapy (MDT) in paucibacillary (PB) leprosy patients.
- To determine the optimal number of MDT doses required for PB leprosy treatment.
- To assess the long-term outcomes of MDT in PB leprosy.
Main Methods:
- A cohort of 736 paucibacillary (PB) leprosy patients were administered multidrug therapy (MDT).
- Patients received MDT for a minimum of 6 months.
- Treatment outcomes, including disease activity, were monitored post-therapy.
Main Results:
- After 6 doses of MDT, 44% of PB patients achieved inactive disease.
- After 12 doses of MDT, 69% of PB patients achieved inactive disease.
- A significant proportion, 27%, of patients remained active at the time of analysis.
Conclusions:
- At least 12 doses of multidrug therapy (MDT) are recommended for paucibacillary (PB) leprosy patients.
- Treatment duration should be standardized irrespective of leprosy type within the PB classification.
- Further research may explore factors influencing treatment response in the 27% of active cases.